Stay updated on GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page

  1. Check
    8 days ago
    No Change Detected
  2. Check
    15 days ago
    Change Detected
    Summary
    Minor UI and labeling updates were made to the page, including the glossary toggle labels (Show glossary / Hide glossary) and new text such as "Last Update Submitted that Met QC Criteria", "No FEAR Act Data", and "Revision: v3.4.0", while the older phrasing "Last Update Submitted that met QC Criteria", "No FEAR Act data", and "Revision: v3.3.4" were removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-01-23T10:11:04.000Z thumbnail image
  3. Check
    22 days ago
    Change Detected
    Summary
    The page shows a minor revision history update: added Revision: v3.3.4 and removed Revision: v3.3.3. This change does not affect study details or user actions; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-16T06:44:29.000Z thumbnail image
  4. Check
    45 days ago
    Change Detected
    Summary
    Added a Locations section with California, Colorado, Florida, Illinois, Kentucky, Louisiana, New Hampshire, and Virginia; removed HHS Vulnerability Disclosure and the listed state location sections, and updated the revision to v3.3.3.
    Difference
    1.0%
    Check dated 2025-12-24T15:19:29.000Z thumbnail image
  5. Check
    74 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.3.2, replacing the previous v3.2.0. No study-specific information appears to be changed.
    Difference
    0.1%
    Check dated 2025-11-25T14:45:05.000Z thumbnail image
  6. Check
    81 days ago
    Change Detected
    Summary
    A government funding status notice on the page was removed. This change does not affect any study details, eligibility criteria, or results reporting; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-18T07:26:28.000Z thumbnail image
  7. Check
    102 days ago
    Change Detected
    Summary
    No substantive changes detected to the Study Details page for NCT03417882; core sections like eligibility criteria, study design, and participating locations appear unchanged.
    Difference
    0.5%
    Check dated 2025-10-27T20:53:34.000Z thumbnail image

Stay in the know with updates to GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.